DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03181932 (ClinicalTrials.gov)	September 26, 2017	1/6/2017	A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients	A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients	MRSA;Cystic Fibrosis	Drug: Vancomycin inhalation powder;Drug: Placebo inhalation powder	Savara Inc.	NULL	Active, not recruiting	6 Years	N/A	All	200	Phase 3	United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03181932
(ClinicalTrials.gov)

September 26, 2017

1/6/2017

A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients

A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients

MRSA;Cystic Fibrosis

Drug: Vancomycin inhalation powder;Drug: Placebo inhalation powder

Savara Inc.

NULL

Active, not recruiting

6 Years

N/A

All

200

Phase 3

United States;Canada